Adrijana Kekic, Pharmacogenomics Pharmacist and Associate Program Director for Outpatient Pharmacy at Mayo Clinic, joined us to talk about the role of pharmacists in delivering personalized care, and the role of technology in enabling PGx implementation at the point of care. You'll also learn about some challenges and exciting developments in personalized medicine.  

Richard (Curt) Dame, Vice President of Aon Health Solutions Practice, joined us to talk about the deployment of pharmacogenomics into popular health management programs, the successes he has seen through the members' health outcomes, and the future he thinks it has. 

Dave Wolfe, the founder and president of FusionRx, joined us to talk about the current healthcare interoperability landscape and the increasing role of pharmacogenetics (PGx).

Denise Giambalvo of the Midwest Business Group on Health (MBGH) joined us to talk about making informed decisions on healthcare strategy, the top most disabling illnesses and how employers are embracing the emergence of

Danny Sands MD, MPH of Beth Israel Deaconess Medical Center joined us to talk about how our health care system is not working as well as it should for patients and clinicians, nor for the government, employers, and insurance plans that pay for it.

Tom Parry President of the Integrated Benefits Institute (IBI), joined us for a conversation on the value of good health.

Carrie Hurwitz Williams, Principal at McKesson Ventures, joined us for a conversation on emerging trends in precision medicine, pockets of adoption and organizations addressing business challenges facing the health care industry.

Bob Mehr is a business innovator and industry leader who began his career as a Compounding Pharmacist. Bob Mehr has been the President and CEO of Pure Integrative Pharmacy since 1999 opening 14 stores. His experience with precision prescribing goes beyond his practice and has had a tremendous impact on his own health.

Dr. Liam Brunham, Assistant Professor in the Department of Medicine at the University of British Columbia and a Principal Investigator at the UBC Centre for Heart and Lung Innovation join us for a conversation on adverse drug reactions, pharmacogenetics and iPSC.